HF
SABSW icon

HRT Financial’s SAB Biotherapeutics Warrant SABSW Stock Holding History

HRT Financial’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-23,756
Closed -$1K – 3039
2022
Q3 		$1K Sell
23,756
-18,110
-43% -$2.16K ﹤0.01% 2676
2022
Q2 		$6K Sell
41,866
-3,116
-7% -$710 ﹤0.01% 2727
2022
Q1 		$20K Hold
44,982
– – ﹤0.01% 2834
2021
Q4 		$80K Buy
44,982
+5,043
+13% +$9.26K ﹤0.01% 2796
2021
Q3 		$35K Buy
+39,939
New +$28.5K ﹤0.01% 3092
2021
Q2 		– Sell
-21,060
Closed -$12K – 3446
2021
Q1 		$12K Buy
+21,060
New +$21.9K ﹤0.01% 2611

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

HRT Financial's SABSW Position: Q4 2022 in Review

HRT Financial sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2022, closing a stake of 23,756 shares — an estimated $1K sold.

HRT Financial first reported a position in SABSW in Q1 2021 and held it in 6 quarters. The position peaked at $80K in Q4 2021. 13 funds tracked by Wall St. Rank hold SABSW as of Q4 2022.

  • HRT Financial reported no remaining SAB Biotherapeutics Warrant position as of Q4 2022 after selling out during the quarter.
  • HRT Financial sold 23,756 SAB Biotherapeutics Warrant shares in Q4 2022, an estimated $1K.
  • HRT Financial first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 6 quarters.
  • HRT Financial's SAB Biotherapeutics Warrant position peaked at $80K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2022.

Based on HRT Financial's 13F filing for Q4 2022, filed 10 Feb 2023.